Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Feb 9;3(1):12-19.
doi: 10.1016/j.ncrna.2018.02.001. eCollection 2018 Mar.

The noncoding-RNA landscape in cardiovascular health and disease

Affiliations
Review

The noncoding-RNA landscape in cardiovascular health and disease

Vittoria Di Mauro et al. Noncoding RNA Res. .

Erratum in

Abstract

The cardiovascular system plays a pivotal role in regulating and maintaining homeostasis in the human body. Therefore any alteration in regulatory networks that orchestrate heart development as well as adaptation to physiological and environmental stress might result in pathological conditions, which represent the leading cause of death worldwide [1]. The latest advances in genome-wide techniques challenged the "protein-central dogma" with the discovery of the so-called non-coding RNAs (ncRNAs). Despite their lack of protein coding potential, ncRNAs have been largely demonstrated to regulate the majority of biological processes and have also been largely implicated in cardiovascular disorders. This review will first discuss the important mechanistic aspects of some of the classes of ncRNAs such as biogenesis, mechanism of action, as well as their involvement in cardiac diseases. The ncRNA potential uses as therapeutic molecules, with a specific focus on the latest technologies for their in vivo delivery as drug targets, will be described.

PubMed Disclaimer

References

    1. Olson E.N. A decade of discoveries in cardiac biology. Nat. Med. 2004;10(5):467–474. - PubMed
    1. Ptaszek L.M. Towards regenerative therapy for cardiac disease. Lancet. 2012;379(9819):933–942. - PubMed
    1. Ho Y.T., Poinard B., Kah J.C.Y. Nanoparticle drug delivery systems and their use in cardiac tissue therapy. Nanomedicine. 2016;11(6):693–714. - PubMed
    1. Hastings C.L. Drug and cell delivery for cardiac regeneration. Adv. Drug Deliv. Rev. 2015;84:85–106. - PubMed
    1. Poller W. Cardiac-targeted delivery of regulatory RNA molecules and genes for the treatment of heart failure. Cardiovasc. Res. 2010;86(3):353–364. - PMC - PubMed

LinkOut - more resources